CAHNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends June 30
CARDINAL HEALTH INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 11, 2026
$252.65−1.41 (-0.55%)
Close on Oct 19, 2026
- Market cap
- $59.12B
- P/E (TTM)
- 34.9
- Dividend yield
- 0.81%
CARDINAL HEALTH INC revenue by segment
By business segment
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical and Specialty Solutions | $234.83B | $231.36B | $225.68B | $215.86B | $204.64B | $204.88B | $205.07B | $207.42B | $210.02B | $203.79B | $199.66B | – | 92.4% | +14.8% |
| GMPD | $12.72B | $12.79B | $12.80B | $12.70B | $12.64B | $12.55B | $12.50B | $12.47B | $12.38B | $12.35B | $12.23B | – | 5.0% | +0.7% |
| Other Operating Segment | $6.79B | $6.68B | $6.28B | $5.84B | $5.38B | $4.95B | $4.80B | $4.65B | $4.51B | $4.32B | $4.19B | – | 2.7% | +26.2% |
| Pharmaceutical | – | – | – | – | – | – | – | – | – | – | $201.03B | $195.19B | – | – |
| Operating income | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical and Specialty Solutions | $2.78B | $2.67B | $2.55B | $2.40B | $2.26B | $2.21B | $2.13B | $2.09B | $2.02B | $2.02B | $2.00B | – | +23.3% |
| Other Operating Segment | $707.00M | $684.00M | $639.00M | $578.00M | $516.00M | $467.00M | $443.00M | $431.00M | $423.00M | $403.00M | $399.00M | – | +37.0% |
| GMPD | $258.00M | $178.00M | $192.00M | $173.00M | $135.00M | $112.00M | $95.00M | $88.00M | $92.00M | $73.00M | $5.00M | – | +91.1% |
| Pharmaceutical | – | – | – | – | – | – | – | – | – | – | $2.13B | $2.08B | – |
By product or service
By region
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $252.64B | $249.12B | $243.07B | $232.71B | $220.99B | $220.70B | $220.66B | $222.85B | $225.23B | $221.04B | $215.92B | $209.20B | 99.4% | +14.3% |
| Non-US [Member] | $1.71B | $1.71B | $1.69B | $1.68B | $1.67B | $1.68B | $1.70B | $1.69B | $1.68B | $2.45B | $3.19B | $3.91B | 0.7% | +2.2% |
From the segment and revenue-disaggregation notes of Cardinal Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.